Investing.com – Pfizer (NYSE:PFE) Q3 adjusted/diluted EPS $0.61 vs estimate $0.62; year earlier $0.60.
Revenues rose 8% from a year earlier to $13.05 bn, just short of estimate of $13.06 bn.
Pfizer narrows full-year EPS guidance range to $2.38-$2.43 from $2.38-$2.48.
Revenues guidance range adjusted to $52-$53 bn from $51-$53 bn.
Pfizer shares up 0.7% at $31.92 in pre-market trade.